NCT06931613Enrolling by invitationPhase 2
Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment
Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment With or Without Bendamustine
Source: ClinicalTrials.gov · Last updated 17 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Children with relapsed or refractory Hodgkin lymphoma receive 3-6 cycles of nivolumab monotherapy. In case of achieving complete response (CR) auto-HSCT is performed. In the absence of CR, 3-6 additional cycles of nivolumab with bendamustine are administered. If complete or partial response is achieved, auto-HSCT is performed.
- Status (registry)
- Enrolling by invitation
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 9 Apr 2025
- Start date
- 1 Jun 2022
- Primary completion date
- 1 Jun 2026
- Lead sponsor
- St. Petersburg State Pavlov Medical University
- Diseases
- Hodgkin lymphoma, Childhood cancers
- NCT number
- NCT06931613
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 20
- From 1 Jun 2022 to the primary completion date, 1 Jun 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Number of previous lines of therapy ≤ 2
- Intolerance to drugs used in the study
- Presence of concomitant severe disease
Other illness
- Presence of HIV and/or viral hepatitis (B or C)
Other
- Karnofsky index \< 60
- Presence of a second tumor
- Pregnancy or lactation
- Participation in another study within six months
Who the study is looking for
- Diagnosis of Hodgkin lymphoma established on the basis of histological and immunohistochemical studies
- Confirmation of relapsed of refractory Hodgkin lymphoma based on histological and immunohistochemical studies or based on imaging methods (PET/CT and/or CT).
- Number of previous lines of therapy \>2
- Karnofsky index ≥60%
- availability of signed informed consent -
Age in the registry: 2 years to 18 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| N. N. Blokhin Russian Cancer Research Center, Moscow, Russia Coordinator of this site? Confirm its status | Moscow | Russia | Unknown status |
| Pavlov University, RM Gorbacheva Research Institute Coordinator of this site? Confirm its status | Saint Petersburg | Russia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.